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Abstract In Japan and Australia, multidrug-resistant
Mycoplasma genitalium infections are reported with increas-
ing frequency. Although macrolide-resistant M. genitalium
strains are common in Europe and North America,
fluoroquinolone-resistant strains are still exceptional.
However, an increase of multidrug-resistant M. genitalium in
Europe and America is to be expected. The aim of this paper is
to increase awareness on the rising number of multidrug-
resistant M. genitalium strains. Here, one of the first cases of
infection with a genetically proven multidrug-resistant
M. genitalium strain in Europe is described. The patient was
a native Dutch 47-year-old male patient with urethritis.
Mycoplasma genitalium was detected, but treatment failed
with azithromycin, doxycycline and moxifloxacin. A urogen-
ital sample was used to determine the sequence of the 23S
rRNA, gyrA, gyrB and parC genes. The sample contained
an A2059G single nucleotide polymorphism (SNP) in the
23S rRNA gene and an SNP in the parC gene, resulting in
an amino acid change of Ser83 → Ile, explaining both
azithromycin and moxifloxacin treatment failure. The SNPs
associated with resistance were probably generated de novo,
as a link with high-prevalence areas was not established. It is,
thus, predictable that there is going to be an increase of
multidrug-resistant M. genitalium strains in Europe. As
treatment options for multidrug-resistant M. genitalium are
limited, the treatment of M. genitalium infections needs to
be carefully considered in order to limit the rapid increase of
resistance to macrolides and fluoroquinolones.
Introduction
Mycoplasma genitalium infects between 1.0 and 3.5% of sex-
ually active people in the general European population [1–3]
and is slightly higher (up to 6.0%) in patients from sexually
transmitted infection (STI) screenings [4–6]. Infection with
M. genitalium causes non-gonococcal urethritis (NGU) in
men [7] and urethritis, cervicitis [8], pelvic inflammatory dis-
ease (PID) [9, 10] and possibly tubal factor infertility in wom-
en [10, 11]. In Europe, azithromycin is currently the preferred
therapy and, when this treatment fails, fluoroquinolones are
used for second-line therapy [12].
Approximately 40% of the M. genitalium strains are resis-
tant to azithromycin [13]. In addition, multidrug-resistant
M. genitalium strains are frequently reported in the Pacific:
in Australia, multidrug-resistant M. genitalium strains were
identified in 9.8% [14] and in Japan in up to 30.8% of the
patients screening for STIs [15]. While in the United States
and Europe macrolide-resistant strains are common,
fluoroquinolone-resistant strains are still quite exceptional.
The first genetically proven fluoroquinolone-resistant strain
in Europe was described by Pond et al. in the UK [16]. This
strain possessed no macrolide resistance-associated mutation,
since it could be treated successfully with azithromycin and
the patient had no symptoms during the 5-month follow-up
period. It is to be expected that an increasing number of the
circulatingM. genitalium strains in Europe would be resistant
to both macrolides and fluoroquinolones. However, there are
almost no peer-reviewed reports on the occurrence of
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multidrug resistance in Europe or the United States of
America. To our knowledge, only a single European case of
infection with a multidrug-resistant strain has been reported
and, unfortunately, the genetic basis of this multidrug-resistant
isolate was not described [17].
Resistance to macrolides is associated with mutations at
positions 2058 and 2059 (Escherichia coli numbering) in re-
gion 5 (V-region) of the 23S rRNA gene [18]. Moxifloxacin
resistance has been described to result from mutations in the
gyrA and parC genes [16]. In this article, one of the first
genetically documented European cases of a multidrug-
resistantM. genitalium infection that has resulted in treatment
failure is described.
Materials and methods
Mycoplasma genitalium was detected in a native Dutch 47-
year-old male patient with urethritis. The patient repeatedly
tested negative by routine polymerase chain reaction (PCR)
assays for Chlamydia trachomatis, Neisseria gonorrhoeae
and Trichomonas vaginalis, and no other pathogen was de-
tected using culture. The patient was initially treated with a
single dose of 1 g of azithromycin. When this failed, he con-
secutively received azithromycin for 5 days, moxifloxacin
400 mg once daily for 10 days, doxycycline 100 mg twice
daily for 7 days and, ultimately, moxifloxacin again 400 mg
once daily for 14 days. After finishing the last antibiotic treat-
ment, the patient still complained of an intermittent burning
sensation and minimal penile discharge. The patient did not
have sexual intercourse during the last months of treatment.
Since azithromycin and moxifloxacin resistance was
suspected, the latest urogenital sample obtained four weeks
after completion of this cure was used for determining the
sequence of the 23S rRNA gene according to the method of
Nijhuis et al. [19] and gyrA, gyrB and parC genes according to
Pond et al. [16].
Results and discussion
The strain harboured an A2059G mutation in the 23S rRNA
gene. This mutation is known to result in azithromycin resis-
tance [18] and, thus, explains the azithromycin resistance of
this strain. In addition, a single nucleotide polymorphism
(SNP) in the parC gene resulting in an amino acid change of
Ser83 → Ile was observed, explaining the resistance to
moxifloxacin [16]. We cannot completely exclude that the
obtained SNPs result from a mixed infection with one strain
that is resistant to azithromycin but sensitive to moxifloxacin,
and a second strain that is sensitive to azithromycin and resis-
tant to moxifloxacin. This is unlikely, as we sequenced direct-
ly on the PCR products obtained from the urogenital sample
and only a single peak was detected at the positions of these
two resistance-associated SNPs. In addition, the infection
could not be resolved by antibiotic treatment and sequences
were obtained from a sample after treatment of the patient with
azithromycin and moxifloxacin, making it very likely that
both SNPs exist in the same isolate. Both resistance mecha-
nisms are based on single-point mutations and, as the patient
had no known contacts with individuals of Asian or Pacific
origin, it is, therefore, most likely that these SNPs were de-
rived de novo.
Resistance to macrolides inM. genitalium is rapidly increas-
ing.Most countries use a single-dosemacrolide for the treatment
of both C. trachomatis and M. genitalium. While still effective
for the treatment of C. trachomatis, the efficacy of 1 g of
azithromycin forM. genitalium has decreased from 85.3% prior
to 2009 to 67.0% after 2009, and is now as low as 60.0% [13].
This rapid increase in resistance to macrolides can partly be
explained by the resistance mechanism ofM. genitalium, where
a change of only one single nucleotide results in resistance to
azithromycin and related macrolide drugs.
Although a bit more complex, an SNP in the gyrA, gyrB and
parC genes can result in fluoroquinolone resistance [20]. In
Japan, fluoroquinolones (in particular, levofloxacin) are fre-
quently used for the treatment of C. trachomatis [21]. As
levofloxacin is not very effective against M. genitalium [22,
23], treatment results in induction of quinolone resistance in
M. genitalium strains potentially present in these patients. As
a consequence, fluoroquinolone resistance in Japan is rapidly
increasing. One study revealed that the prevalence of fluoro-
quinolone resistance with proven SNP in the parC gene in
Japan between 2006 and 2008was 10.7% [24]. This prevalence
further increased to 47.1% in 2013 [21]. In other areas in the
Pacific, a similar increase in fluoroquinolone resistance has
been reported [25]. As the first-choice regimens for treating
M. genitalium are based on either azithromycin or moxifloxacin
(or closely related macrolides/fluoroquinolones) and alternative
treatment options are limited, isolates resistant to azithromycin
and moxifloxacin will be very difficult to eradicate [12]. Such
multidrug-resistant M. genitalium strains can effectively be
treated with pristinamycin [26]. However, pristinamycin is ex-
pensive and not widely available [25], which makes the treat-
ment of multidrug-resistant M. genitalium challenging.
To the best of our knowledge, we describe here one of the
first genetically documented multidrug-resistantM. genitalium
strains in Europe. Since microbiological cure was not expected
with any other available antibiotic in our patient and the patient
eventually had only minor complaints, he declined further
treatment. The origin of the infecting strain seemed to be in
The Netherlands and was probably derived from de novo mu-
tations selected by antibiotic therapy. Since macrolide resis-
tance has increased over time in M. genitalium, it seems plau-
sible that fluoroquinolone resistance will become more preva-
lent in the near future. The efficacy of current treatment
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protocols for M. genitalium is, therefore, seriously threatened,
since treatment options are limited. Guideline-based treatment
and restrictive antibiotic use are crucial in limiting antibiotic
resistance. Future studies are needed to assess the clinical im-
pact of emerging fluoroquinolone resistance in Europe.
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